

Robert A Wise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6392675/publications.pdf>

Version: 2024-02-01

412
papers

31,263
citations

4388

86
h-index

5679

162
g-index

427
all docs

427
docs citations

427
times ranked

22116
citing authors

#	ARTICLE	IF	CITATIONS
1	It is kind of like a responsibility thing – transitional challenges in asthma medication adherence among adolescents and young adults. <i>Journal of Asthma</i> , 2022, 59, 956-966.	1.7	7
2	Comparative Impact of Depressive Symptoms and FEV ₁ % on Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 171-178.	3.2	7
3	Clinically Significant and Comorbid Anxiety and Depression Symptoms Predict Severe Respiratory Exacerbations in Smokers: A <i>Post Hoc</i> Analysis of the COPD Gene and SPIROMICS Cohorts. <i>Annals of the American Thoracic Society</i> , 2022, 19, 143-146.	3.2	6
4	Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health: Results of the CLEAN AIR Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 421-430.	5.6	41
5	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2022, 19, 204-213.	3.2	18
6	Race, Lung Function, and Long-Term Mortality in the National Health and Nutrition Examination Survey III. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 723-724.	5.6	46
7	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	5.6	72
8	The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. <i>American Journal of Medicine</i> , 2022, 135, 302-312.	1.5	10
9	Home Dust Allergen Exposure Is Associated with Outcomes among Sensitized Individuals with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 412-420.	5.6	6
10	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	5.6	21
11	Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. <i>Thorax</i> , 2022, 77, 1088-1097.	5.6	8
12	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 151.	7.4	31
13	Evaluating construct validity of the Asthma Impairment and Risk Questionnaire using a 3-month exacerbation recall. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 544-552.e3.	1.0	6
14	An Online Weight Loss Intervention for People With Obesity and Poorly Controlled Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1577-1586.e3.	3.8	16
15	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 25-33.	5.6	11
16	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 97.	3.6	7
17	Comparing Self-Management Programs with and without Peer Support among Patients with Chronic Obstructive Pulmonary Disease: A Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1687-1696.	3.2	1
18	Depressive and anxiety symptoms in patients with COPD: A network analysis. <i>Respiratory Medicine</i> , 2022, 198, 106865.	2.9	15

#	ARTICLE	IF	CITATIONS
19	Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 838-845.	5.6	12
20	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. <i>Chest</i> , 2021, 159, 985-995.	0.8	6
21	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. <i>Pulmonary Therapy</i> , 2021, 7, 101-118.	2.2	6
22	Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 153-159.	2.5	9
23	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , 2021, 7, 00663-2020.	2.6	7
24	Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 371-381.	0.7	2
25	Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 277-291.	0.7	1
26	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 326-335.	0.7	0
27	Metformin use and respiratory outcomes in asthma-COPD overlap. <i>Respiratory Research</i> , 2021, 22, 70.	3.6	21
28	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 213.	1.6	4
29	The influence of social support on COPD outcomes mediated by depression. <i>PLoS ONE</i> , 2021, 16, e0245478.	2.5	8
30	The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 689-699.	2.3	0
31	InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. <i>Respiratory Research</i> , 2021, 22, 130.	3.6	9
32	Reply to Lpez-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 928-929.	5.6	1
33	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. <i>Annals of the American Thoracic Society</i> , 2021, 18, 788-798.	3.2	19
34	Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPD Gene Cohort. <i>Chest</i> , 2021, 160, 1245-1254.	0.8	9
35	Factors Associated with Persistence of Severe Asthma from Late Adolescence to Early Adulthood. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 776-787.	5.6	16
36	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021, 7, 00902-2020.	2.6	15

#	ARTICLE	IF	CITATIONS
37	Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease. <i>ERJ Open Research</i> , 2021, 7, 00068-2021.	2.6	6
38	Acclidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1093-1106.	2.5	3
39	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. <i>European Respiratory Journal</i> , 2021, 58, 2004522.	6.7	4
40	Efficacy of Acclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. <i>Advances in Therapy</i> , 2021, 38, 5381-5397.	2.9	0
41	Indoor Environmental Factors May Modify the Response to Mouse Allergen Reduction Among Mouse-Sensitized and Exposed Children with Persistent Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4402-4409.e2.	3.8	9
42	InforMing the PATHway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf s in Patients With COPD: Analysis of the Western Europe and North America Regions. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla.)</i> , 2021, 8, 76-90.	0.7	1
43	Losartan Effects on Emphysema Progression Randomized Clinical Trial: Rationale, Design, Recruitment, and Retention. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla.)</i> , 2021, 8, 414-426.	0.7	4
44	A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. <i>European Respiratory Journal</i> , 2021, 57, 2003103.	6.7	38
45	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. <i>Respiratory Research</i> , 2021, 22, 272.	3.6	1
46	Discordant diagnostic criteria for pneumonia in COPD trials: a review. <i>European Respiratory Review</i> , 2021, 30, 210124.	7.1	8
47	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla.)</i> , 2021, , .	0.7	3
48	Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME). <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100427.	1.1	5
49	Obstructive Sleep Apnea and Airway Dimensions in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2020, 17, 116-118.	3.2	6
50	Do Baseline Asthma and Allergic Sensitization Characteristics Predict Responsiveness to Mouse Allergen Reduction?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 596-602.e3.	3.8	7
51	The Effects of Rare <i>SERPINA1</i> Variants on Lung Function and Emphysema in SPIROMICS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 540-554.	5.6	38
52	Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma. <i>Rheumatology</i> , 2020, 59, 790-798.	1.9	3
53	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 294-302.	5.6	56
54	Reduction in mouse allergen exposure is associated with greater lung function growth. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 646-653.e1.	2.9	32

#	ARTICLE	IF	CITATIONS
55	THE AUTHORS REPLY. American Journal of Epidemiology, 2020, 189, 482-482.	3.4	0
56	Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 219-226.	2.1	7
57	Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3474-3481.	3.8	7
58	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy, 2020, 37, 3775-3790.	2.9	9
59	<p>A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings</p>. International Journal of COPD, 2020, Volume 15, 2769-2777.	2.3	12
60	Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD. ERJ Open Research, 2020, 6, 00177-2019.	2.6	4
61	Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 297-305.	1.6	21
62	Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2263-2274.e5.	3.8	25
63	Methodology and baseline characteristics of a randomized controlled trial testing a health care professional and peer-support program for patients with chronic obstructive pulmonary disease: The BREATHE2 study. Contemporary Clinical Trials, 2020, 94, 106023.	1.8	7
64	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research, 2020, 21, 139.	3.6	9
65	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	5.6	151
66	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	5.6	28
67	Associations Among 25-Hydroxyvitamin D&ALevels, Lung Function, and Exacerbation Outcomes in COPD. Chest, 2020, 157, 856-865.	0.8	35
68	Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life. Chest, 2020, 158, 529-538.	0.8	8
69	The effect of exacerbation history on outcomes in the IMPACT trial. European Respiratory Journal, 2020, 55, 1901921.	6.7	24
70	Clinical Phenotypes of Atopy and Asthma in COPD. Chest, 2020, 158, 2333-2345.	0.8	19
71	Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. Journal of Clinical Investigation, 2020, 130, 3750-3760.	8.2	78
72	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 370-381.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. <i>Clinical Trials</i> , 2020, 17, 430-436.	1.6	2
74	The COPD Foundation Coronavirus Disease 2019 International Medical Experts Survey: Results. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 139-146.	0.7	1
75	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 473-481.	5.6	1
76	Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 395-402.e7.	2.9	2
77	Clinical characterization of children with resistant airflow obstruction, a multicenter study. <i>Journal of Asthma</i> , 2019, 56, 611-617.	1.7	2
78	Identifying an at-risk population for poor asthma outcomes: Data from the American Lung Association Asthma Clinical Trials Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2872-2874.	3.8	1
79	Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results. <i>Diabetes Care</i> , 2019, 42, 1708-1715.	8.6	4
80	Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. <i>Respiratory Research</i> , 2019, 20, 190.	3.6	16
81	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 745-756.	10.7	159
82	Notice of Retraction. Aboumatar et al. Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. <i>JAMA</i> . 2018;320(22):2335-2343.. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1417.	7.4	13
83	Misinterpretation of time-to-first event curves can lead to inappropriate treatment. <i>European Respiratory Journal</i> , 2019, 54, 1900634.	6.7	7
84	Diffusing Capacity of Carbon Monoxide in Assessment of COPD. <i>Chest</i> , 2019, 156, 1111-1119.	0.8	58
85	Investigation of the Obesity Paradox in Chronic Obstructive Pulmonary Disease, According to Smoking Status, in the United States. <i>American Journal of Epidemiology</i> , 2019, 188, 1977-1983.	3.4	21
86	Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1371.	7.4	75
87	Aspirin Use and Respiratory Morbidity in COPD. <i>Chest</i> , 2019, 155, 519-527.	0.8	25
88	BMI but not central obesity predisposes to airway closure during bronchoconstriction. <i>Respirology</i> , 2019, 24, 543-550.	2.3	26
89	Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD. <i>European Respiratory Journal</i> , 2019, 54, 1900088.	6.7	18
90	Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. <i>Respiratory Research</i> , 2019, 20, 86.	3.6	16

#	ARTICLE	IF	CITATIONS
91	Self-medication as Part of Self-management Plans for Patients With COPD—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1937.	7.4	2
92	Effect of Acclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1693.	7.4	25
93	The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. <i>Chest</i> , 2019, 156, 685-695.	0.8	40
94	The health and social implications of household air pollution and respiratory diseases. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 12.	2.6	70
95	Plasma cathelicidin and longitudinal lung function in current and former smokers. <i>PLoS ONE</i> , 2019, 14, e0212628.	2.5	11
96	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019, 16, 826-835.	3.2	41
97	Older age and obesity are associated with increased airway closure in response to methacholine in patients with asthma. <i>Respirology</i> , 2019, 24, 638-645.	2.3	18
98	Multimorbidity at sea level and high-altitude urban and rural settings: The CRONICAS Cohort Study. <i>Journal of Comorbidity</i> , 2019, 9, 2235042X1987529.	3.9	17
99	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. <i>Annals of the American Thoracic Society</i> , 2019, 16, 200-208.	3.2	31
100	Validation of the maximum symptom day among children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 803-805.e10.	2.9	12
101	Does Obesity Increase Respiratory Tract Infections in Patients with Asthma?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 954-961.e6.	3.8	12
102	Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019, 16, 217-224.	3.2	75
103	Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1598-1606.	2.9	38
104	Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. <i>Journal of Psychosomatic Research</i> , 2019, 118, 18-26.	2.6	21
105	Prevalence of chronic respiratory disease in urban and rural Uganda. <i>Bulletin of the World Health Organization</i> , 2019, 97, 318-327.	3.3	41
106	Celebration of the 50-Year Anniversary of the National Heart, Lung, and Blood Institute Division of Lung Diseases: A Half-Century of Landmark Clinical Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 359-370.	0.7	0
107	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 210-220.	0.7	3
108	Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. <i>Respiratory Research</i> , 2018, 19, 20.	3.6	20

#	ARTICLE	IF	CITATIONS
109	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <i>New England Journal of Medicine</i> , 2018, 378, 1671-1680.	27.0	823
110	Patterns of Body Composition Relating to Chronic Respiratory Diseases Among Adults in Four Resource-Poor Settings in Peru. <i>Lung</i> , 2018, 196, 277-284.	3.3	3
111	Asthma and Allergic Disorders in Uganda: A Population-Based Study Across Urban and Rural Settings. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1580-1587.e2.	3.8	23
112	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. <i>Thorax</i> , 2018, 73, 414-421.	5.6	96
113	Association between Household Air Pollution Exposure and Chronic Obstructive Pulmonary Disease Outcomes in 13 Low- and Middle-Income Country Settings. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 611-620.	5.6	129
114	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2037-2047.e10.	2.9	138
115	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. <i>Annals of the American Thoracic Society</i> , 2018, 15, 808-816.	3.2	32
116	A new measure to assess asthma's effect on quality of life from the patient's perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1085-1095.	2.9	6
117	Validity of the Asthma Control Test Questionnaire Among Smoking Asthmatics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 151-158.	3.8	6
118	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. <i>Annals of the American Thoracic Society</i> , 2018, 15, 89-101.	3.2	8
119	Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 633-643.e1.	3.8	19
120	The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants. <i>Annals of the American Thoracic Society</i> , 2018, 15, 200-208.	3.2	16
121	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. <i>Chest</i> , 2018, 153, 65-76.	0.8	36
122	Validation of the Saint George's Respiratory Questionnaire in Uganda. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000276.	3.0	10
123	Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2335.	7.4	40
124	Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary disease. <i>ERJ Open Research</i> , 2018, 4, 00069-2018.	2.6	11
125	Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 53, 27-32.	2.6	5
126	Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1297-1308.	2.3	15

#	ARTICLE	IF	CITATIONS
127	Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR^{®®} trial. International Journal of COPD, 2018, Volume 13, 605-616.	2.3	18
128	Medication Regimens for Managing COPD Exacerbations. Respiratory Care, 2018, 63, 773-782.	1.6	3
129	Environmental exposures and systemic hypertension are risk factors for decline in lung function. Thorax, 2018, 73, 1120-1127.	5.6	16
130	Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2018, 15, 926-934.	3.2	32
131	The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. International Journal of COPD, 2018, Volume 13, 1009-1019.	2.3	42
132	Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS ONE, 2018, 13, e0194924.	2.5	25
133	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals of the American Thoracic Society, 2018, 15, 710-717.	3.2	32
134	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPD Gene Study. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1397-1405.	5.6	132
135	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 47-55.	5.6	46
136	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 5-15.	0.7	7
137	Long-Term Oxygen for COPD. New England Journal of Medicine, 2017, 376, 286-287.	27.0	3
138	Do Patients Hospitalized With COPD Have Airflow Obstruction?. Chest, 2017, 151, 1263-1271.	0.8	25
139	Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma. JAMA - Journal of the American Medical Association, 2017, 317, 1027.	7.4	96
140	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	2.9	55
141	Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. EBioMedicine, 2017, 19, 139-145.	6.1	27
142	HIV Infection Is Independently Associated with Increased CT Scan Lung Density. Academic Radiology, 2017, 24, 137-145.	2.5	11
143	American Thoracic Society/National Heart, Lung, and Blood Institute Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 375-381.	5.6	86
144	Response. Chest, 2017, 151, 1397-1398.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Effect of intranasal corticosteroids on allergic airway disease in asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1125-1128.e3.	3.8	3
146	Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. <i>Journal of General Internal Medicine</i> , 2017, 32, 1315-1322.	2.6	73
147	Reproducibility of airway luminal size in asthma measured by HRCT. <i>Journal of Applied Physiology</i> , 2017, 123, 876-883.	2.5	4
148	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017, 5, 956-967.	10.7	211
149	Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25 ⁷⁵ /FVC) in COPD. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000231.	3.0	18
150	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017, 5, 619-626.	10.7	219
151	Discordance in investigator-reported and adjudicated sudden death in TIOSPIR. <i>ERJ Open Research</i> , 2017, 3, 00073-2016.	2.6	5
152	Fluctuation Analysis of Peak Expiratory Flow and Its Association with Treatment Failure in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 993-999.	5.6	24
153	Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. <i>Chest</i> , 2017, 151, 68-77.	0.8	113
154	Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. <i>Journal of the American Medical Association</i> , 2017, 318, 1063-1068.	2.5	8
155	Electronic cigarette use behaviors and motivations among smokers and non-smokers. <i>BMC Public Health</i> , 2017, 17, 686.	2.9	28
156	Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. <i>International Journal of COPD</i> , 2017, Volume 12, 3391-3405.	2.3	40
157	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 7-20.	0.7	9
158	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 177-185.	0.7	22
159	Recruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons Learned. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 265-278.	0.7	5
160	A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 186-193.	0.7	4
161	Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR ^{reg} trial. <i>International Journal of COPD</i> , 2016, 11, 133.	2.3	4
162	National priorities for perioperative research in South Africa. <i>South African Medical Journal</i> , 2016, 106, 485.	0.6	12

#	ARTICLE	IF	CITATIONS
163	Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1940-1950.	3.2	29
164	Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1465-1474.	5.6	20
165	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1016-1025.	3.2	36
166	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. <i>Thorax</i> , 2016, 71, 411-420.	5.6	14
167	Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1571-1579.e10.	2.9	44
168	Implementation of a COPD Screening Questionnaire in an Outpatient HIV Clinic. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 767-772.	1.6	11
169	Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. <i>New England Journal of Medicine</i> , 2016, 374, 1842-1852.	27.0	456
170	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. <i>Cmaj</i> , 2016, 188, 1004-1011.	2.0	38
171	Asthma—Chronic Obstructive Pulmonary Disease Overlap Syndrome. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 515-528.	1.9	16
172	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	10.7	754
173	HIV Suppression Restores the Lung Mucosal CD4 ⁺ T-Cell Viral Immune Response and Resolves CD8 ⁺ T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease. <i>Journal of Infectious Diseases</i> , 2016, 214, 1520-1530.	4.0	26
174	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. <i>Respiratory Medicine</i> , 2016, 120, 91-100.	2.9	4
175	Measurement characteristics of the childhood Asthma-Control Test and a shortened, child-only version. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16075.	2.6	34
176	Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches. <i>Respiratory Medicine</i> , 2016, 121, 59-66.	2.9	34
177	A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. <i>New England Journal of Medicine</i> , 2016, 375, 1617-1627.	27.0	327
178	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2016, 16, 65.	2.0	18
179	Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude. <i>High Altitude Medicine and Biology</i> , 2016, 17, 93-100.	0.9	38
180	Tiotropium safety in “real-world” populations. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 562-563.	2.4	3

#	ARTICLE	IF	CITATIONS
181	Association Between Expiratory Central Airway Collapse and Respiratory Outcomes Among Smokers. JAMA - Journal of the American Medical Association, 2016, 315, 498.	7.4	67
182	Gastro-oesophageal reflux and worse asthma control in obese children: a case of symptom misattribution?. Thorax, 2016, 71, 238-246.	5.6	24
183	Association between Functional Small Airway Disease and FEV ₁ Decline in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 178-184.	5.6	292
184	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respiratory Medicine, 2016, 111, 30-38.	2.9	9
185	Urbanisation but not biomass fuel smoke exposure is associated with asthma prevalence in four resource-limited settings. Thorax, 2016, 71, 154-160.	5.6	42
186	Urbanization and Daily Exposure to Biomass Fuel Smoke Both Contribute to Chronic Bronchitis Risk in a Population with Low Prevalence of Daily Tobacco Smoking. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 186-195.	1.6	22
187	Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE, 2016, 11, e0163716.	2.5	92
188	High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami, Tj ETQq0 0 OrgBT /Overlock 10 T		
189	Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension. Chest, 2015, 147, 188-197.	0.8	60
190	Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open, 2015, 5, e009015.	1.9	8
191	Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. Npj Primary Care Respiratory Medicine, 2015, 25, 15067.	2.6	14
192	The Tiotropium Safety and Performance in Respimat® (TIOPIR®) Trial: Spirometry Outcomes. Respiratory Research, 2015, 16, 107.	3.6	19
193	HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 68-74.	2.1	42
194	The relationship between Helicobacter pylori seropositivity and COPD. Thorax, 2015, 70, 923-929.	5.6	22
195	Effect of a Soy Isoflavone Supplement on Lung Function and Clinical Outcomes in Patients With Poorly Controlled Asthma. JAMA - Journal of the American Medical Association, 2015, 313, 2033.	7.4	41
196	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	7.1	72
197	Caesarean section and anaesthetic mortality. Southern African Journal of Anaesthesia and Analgesia, 2015, 21, 145-145.	0.3	1
198	Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPD Gene study. Respiratory Research, 2015, 16, 115.	3.6	59

#	ARTICLE	IF	CITATIONS
199	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 212-213.	2.9	0
200	Characteristics of Alpha-1 Antitrypsinâ€“Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1796-1804.	3.2	15
201	Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 701-709.e5.	2.9	48
202	Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 226-234.	2.9	27
203	Serum Bilirubin and Disease Progression in Mild COPD. <i>Chest</i> , 2015, 148, 169-175.	0.8	27
204	Relationship Between Daily Exposure to Biomass Fuel Smoke and Blood Pressure in High-Altitude Peru. <i>Hypertension</i> , 2015, 65, 1134-1140.	2.7	60
205	Lansoprazole Is Associated with Worsening Asthma Control in Children with the <i>CYP2C19</i> Poor Metabolizer Phenotype. <i>Annals of the American Thoracic Society</i> , 2015, 12, 878-885.	3.2	26
206	Use of mobile devices and the internet for multimedia informed consent delivery and data entry in a pediatric asthma trial: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2015, 42, 105-118.	1.8	28
207	Diagnostic accuracy of FEV1/forced vital capacity ratio z scores in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 649-653.e4.	2.9	8
208	Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. <i>Respiratory Research</i> , 2015, 16, 40.	3.6	61
209	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	5.6	166
210	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	6.7	138
211	Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 575-591.	2.1	144
212	Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude. <i>High Altitude Medicine and Biology</i> , 2015, 16, 162-168.	0.9	8
213	Older Adults with Chronic Lung Disease Report Less Limitation Compared with Younger Adults with Similar Lung Function Impairment. <i>Annals of the American Thoracic Society</i> , 2015, 12, 21-26.	3.2	16
214	Menthol cigarette smoking in the <i>COPDG</i> cohort: Relationship with <i>COPD</i> , comorbidities and <i>CT</i> metrics. <i>Respirology</i> , 2015, 20, 108-114.	2.3	14
215	Telomerase mutations in smokers with severe emphysema. <i>Journal of Clinical Investigation</i> , 2015, 125, 563-570.	8.2	152
216	A Simplified Score to Quantify Comorbidity in COPD. <i>PLoS ONE</i> , 2014, 9, e114438.	2.5	58

#	ARTICLE	IF	CITATIONS
217	Chronic Obstructive Pulmonary Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014, 11, S154-S160.	3.2	21
218	Chronic Productive Cough is Associated with Death in Smokers with Early COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 451-458.	1.6	25
219	Hepatitis C Virus Infection Is Not An Independent Risk Factor For Obstructive Lung Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 10-16.	1.6	10
220	Tiotropium and the Risk of Death in COPD. <i>New England Journal of Medicine</i> , 2014, 370, 480-483.	27.0	24
221	The IBV Valve Trial. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2014, 21, 288-297.	1.4	53
222	Activation-induced Cell Death Drives Profound Lung CD4 ⁺ T-Cell Depletion in HIV-associated Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 744-755.	5.6	42
223	Prevalence, Clinical Profile, Iron Status, and Subject-Specific Traits for Excessive Erythrocytosis in Andean Adults Living Permanently at 3,825 Meters Above Sea Level. <i>Chest</i> , 2014, 146, 1327-1336.	0.8	43
224	Validation and psychometric properties of the Asthma Control Questionnaire among children. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 91-97.e6.	2.9	48
225	The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1060-1066.	0.9	37
226	A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. <i>BMC Public Health</i> , 2014, 14, 761.	2.9	23
227	A cross-sectional study of differences in 6-min walk distance in healthy adults residing at high altitude versus sea level. <i>Extreme Physiology and Medicine</i> , 2014, 3, 3.	2.5	3
228	Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 112, 354-360.e1.	1.0	16
229	Transcriptional responses of neonatal mouse lung to hyperoxia by Nrf2 status. <i>Cytokine</i> , 2014, 65, 4-9.	3.2	40
230	Exhaled Breath Condensate pH Does Not Discriminate Asymptomatic Gastroesophageal Reflux or the Response to Lansoprazole Treatment in Children with Poorly Controlled Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 579-586.e7.	3.8	14
231	The American Lung Association: Asthma Clinical Research Centers network: addressing real life questions in asthma management. <i>Clinical Investigation</i> , 2014, 4, 495-499.	0.0	1
232	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. <i>Chest</i> , 2014, 146, 941-950.	0.8	71
233	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. <i>Journal of Clinical Investigation</i> , 2014, 124, 5521-5521.	8.2	3
234	A Cross Sectional Analysis of the Role of the Antimicrobial Peptide Cathelicidin in Lung Function Impairment within the ALIVE Cohort. <i>PLoS ONE</i> , 2014, 9, e95099.	2.5	20

#	ARTICLE	IF	CITATIONS
235	Comorbidities of COPD Have a Major Impact on Clinical Outcomes, Particularly in African Americans. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 105-114.	0.7	40
236	The Tiotropium Safety and Performance in Respimat [®] Trial (TIOPIR [®]), a large scale, randomized, controlled, parallel-group trial-design and rationale. <i>Respiratory Research</i> , 2013, 14, 40.	3.6	48
237	Tiotropium Respimat Inhaler and the Risk of Death in COPD. <i>New England Journal of Medicine</i> , 2013, 369, 1491-1501.	27.0	318
238	Racial Differences in CT Phenotypes in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 20-27.	1.6	42
239	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. <i>Human Genetics</i> , 2013, 132, 79-90.	3.8	45
240	Biologic Mechanisms of Environmental Tobacco Smoke in Children with Poorly Controlled Asthma: Results from a Multicenter Clinical Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 172-180.e2.	3.8	29
241	Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 491-499.e4.	1.2	30
242	Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children. <i>Journal of Pediatrics</i> , 2013, 163, 686-691.	1.8	47
243	Chronic exposure to biomass fuel is associated with increased carotid artery intima-media thickness and a higher prevalence of atherosclerotic plaque. <i>Heart</i> , 2013, 99, 984-991.	2.9	79
244	Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1413-1419.	5.6	121
245	Obesity in children with poorly controlled asthma: Sex differences. <i>Pediatric Pulmonology</i> , 2013, 48, 847-856.	2.0	34
246	Reply: Prognostic Value of Functional Decline in Middle-Aged Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1029-1029.	5.6	1
247	Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1136-1140.	0.9	19
248	Effect of urbanisation on the relationship between total serum IgE and asthma. <i>European Respiratory Journal</i> , 2013, 41, 1074-1081.	6.7	3
249	A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1962-1967.	0.9	36
250	Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. <i>Arthritis Research and Therapy</i> , 2013, 15, R54.	3.5	25
251	Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. <i>Chest</i> , 2013, 144, 490-497.	0.8	42
252	The Tiotropium Safety and Performance in Respimat (TIOPIR) trial: Bronchodilator efficacy in a spirometry substudy. <i>Chest</i> , 2013, 144, 1027A.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Forced expiratory capnography and chronic obstructive pulmonary disease (COPD). <i>Journal of Breath Research</i> , 2013, 7, 017108.	3.0	8
254	Reply: A Call to Apply the Minimal Important Difference in Pulmonary Arterial Hypertension beyond the Flawed 6-Minute-Walk Test. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 659-659.	5.6	1
255	The effect of HIV infection on longitudinal lung function decline among IDUs. <i>Aids</i> , 2013, 27, 1303-1311.	2.2	112
256	Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema. <i>PLoS ONE</i> , 2013, 8, e56352.	2.5	43
257	The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD). <i>PLoS ONE</i> , 2013, 8, e61315.	2.5	13
258	Measures of asthma control. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 48-56.	2.6	15
259	Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled Trial. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 373-380.	7.4	214
260	Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. <i>Thorax</i> , 2012, 67, 309-314.	5.6	86
261	The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 428-433.	5.6	218
262	Long-Term Intersession Variability for Single-Breath Diffusing Capacity. <i>Respiration</i> , 2012, 84, 377-384.	2.6	7
263	Spirometric Predictors of Lung Function Decline and Mortality in Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1301-1306.	5.6	91
264	Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 398-404.	2.3	20
265	Relationship Between Lung Function Impairment and Health-Related Quality of Life in COPD and Interstitial Lung Disease. <i>Chest</i> , 2012, 142, 704-711.	0.8	28
266	Asthma clinical trials of American Lung Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12 years?. <i>Current Respiratory Care Reports</i> , 2012, 1, 251-258.	0.6	2
267	The Peru Urban versus Rural Asthma (PURA) Study: methods and baseline quality control data from a cross-sectional investigation into the prevalence, severity, genetics, immunology and environmental factors affecting asthma in adolescence in Peru. <i>BMJ Open</i> , 2012, 2, e000421.	1.9	27
268	Optimizing the 6-Min Walk Test as a Measure of Exercise Capacity in COPD. <i>Chest</i> , 2012, 142, 1545-1552.	0.8	27
269	The Complex Relationship of Serum Adiponectin to COPD Outcomes. <i>Chest</i> , 2012, 142, 893-899.	0.8	51
270	Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 112-118.	2.9	119

#	ARTICLE	IF	CITATIONS
271	Methacholine challenge test: Diagnostic characteristics in asthmatic patients receiving controller medications. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 69-75.e6.	2.9	69
272	Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1078-1084.	2.9	41
273	Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 229-240.	8.2	110
274	Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 875-882.	2.9	44
275	The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 406-411.	2.9	31
276	Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. <i>Science Translational Medicine</i> , 2011, 3, 78ra32.	12.4	271
277	Effect of urbanisation on asthma, allergy and airways inflammation in a developing country setting. <i>Thorax</i> , 2011, 66, 1051-1057.	5.6	101
278	Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. <i>International Journal of COPD</i> , 2011, 6, 89.	2.3	31
279	Does Age Impact the Obese Asthma Phenotype?. <i>Chest</i> , 2011, 140, 1524-1533.	0.8	66
280	Risk Factors for Montelukast Treatment Failure in Step-Down Therapy for Controlled Asthma. <i>Journal of Asthma</i> , 2011, 48, 1051-1057.	1.7	10
281	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 317-322.	5.6	157
282	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. <i>Journal of Clinical Investigation</i> , 2011, 121, 4289-4302.	8.2	116
283	Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1187-1192.	5.6	93
284	Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. <i>European Heart Journal</i> , 2011, 32, 1918-1925.	2.2	55
285	Exposure to neonatal cigarette smoke causes durable lung changes but does not potentiate cigarette smoke-induced chronic obstructive pulmonary disease in adult mice. <i>Experimental Lung Research</i> , 2011, 37, 354-363.	1.2	2
286	Neonatal Hyperoxia Contributes Additively to Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Changes in Adult Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 610-616.	2.9	22
287	Chronic intermittent hypoxia induces lung growth in adult mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 300, L266-L273.	2.9	34
288	Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease. <i>Open Rheumatology Journal</i> , 2011, 5, 1-6.	0.2	10

#	ARTICLE	IF	CITATIONS
289	The Effect of Active and Passive Household Cigarette Smoke Exposure on Pregnant Women With Asthma. <i>Chest</i> , 2010, 137, 601-608.	0.8	38
290	HIV and COPD: impact of risk behaviors and diseases on quality of life. <i>Quality of Life Research</i> , 2010, 19, 1295-1302.	3.1	30
291	Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. <i>BMC Pulmonary Medicine</i> , 2010, 10, 27.	2.0	33
292	Aquaporin 5 Polymorphisms and Rate of Lung Function Decline in Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2010, 5, e14226.	2.5	32
293	Physical Activity, Health Status and Risk of Hospitalization in Patients with Severe Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2010, 80, 10-18.	2.6	73
294	Mortality in COPD: Causes, Risk Factors, and Prevention. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 375-382.	1.6	158
295	The Relationship of Asthma-Specific Quality of Life During Pregnancy to Subsequent Asthma and Perinatal Morbidity. <i>Journal of Asthma</i> , 2010, 47, 46-50.	1.7	28
296	Maternal Vitamin A Supplementation and Lung Function in Offspring. <i>New England Journal of Medicine</i> , 2010, 362, 1784-1794.	27.0	186
297	Accuracy of Death Certificates in COPD: Analysis from the TORCH Trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 179-185.	1.6	51
298	Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2010, 104, 1943-1950.	2.9	6
299	Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. <i>Respiratory Research</i> , 2010, 11, 29.	3.6	71
300	Influence of Maternal Asthma and Asthma Severity on Newborn Morphometry. <i>Journal of Asthma</i> , 2010, 47, 145-149.	1.7	6
301	Clinical Significance of Radiologic Characterizations in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 459-467.	1.6	85
302	Criteria To Screen for Chronic Sinonasal Disease. <i>Chest</i> , 2009, 136, 1324-1332.	0.8	51
303	Heightened Endoplasmic Reticulum Stress in the Lungs of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1196-1207.	5.6	150
304	Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. <i>New England Journal of Medicine</i> , 2009, 360, 1487-1499.	27.0	357
305	Effects of Asymptomatic Proximal and Distal Gastroesophageal Reflux on Asthma Severity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 809-816.	5.6	61
306	Integrating Health Status and Survival Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 239-246.	5.6	32

#	ARTICLE	IF	CITATIONS
307	Transforming Growth Factor- β Receptor-3 Is Associated with Pulmonary Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 324-331.	2.9	40
308	Interpretation of Pulmonary Function Test: Issues and Controversies. Clinical Reviews in Allergy and Immunology, 2009, 37, 173-180.	6.5	20
309	Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers. Journal of Allergy and Clinical Immunology, 2009, 124, 436-444.e8.	2.9	94
310	Eosinophil and T cell markers predict functional decline in COPD patients. Respiratory Research, 2009, 10, 113.	3.6	39
311	Respiratory Physiology in Pregnancy. , 2009, , 19-26.		9
312	Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. Journal of Allergy and Clinical Immunology, 2008, 122, 781-787.e8.	2.9	9
313	Sleep Quality in Asthma: Results of a Large Prospective Clinical Trial. Journal of Asthma, 2008, 45, 183-189.	1.7	70
314	Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulmonary Pharmacology and Therapeutics, 2008, 21, 630-636.	2.6	17
315	Exercise Testing in Severe Emphysema: Association with Quality of Life and Lung Function. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 117-124.	1.6	51
316	Intersession Variability in Single-Breath Diffusing Capacity in Diabetics without Overt Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 225-232.	5.6	15
317	Impaired Lung Homeostasis in Neonatal Mice Exposed to Cigarette Smoke. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 393-400.	2.9	33
318	The Role of NETT in Emphysema Research. Proceedings of the American Thoracic Society, 2008, 5, 385-392.	3.5	5
319	Changes in Arterial Oxygenation and Self-Reported Oxygen Use after Lung Volume Reduction Surgery. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 339-345.	5.6	23
320	Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 491-499.	5.6	114
321	Oxygen Therapy in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2008, 5, 513-518.	3.5	123
322	Pulmonary Rehabilitation and Clinical Trial Design in Patients with Severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 305-309.	1.6	2
323	Pharmacokinetics and Metabolism of All- <i>trans</i> - and 13- <i>cis</i> -Retinoic Acid in Pulmonary Emphysema Patients. Journal of Clinical Pharmacology, 2008, 48, 96-107.	2.0	14
324	Continuous Oxygen Use in Nonhypoxemic Emphysema Patients Identifies a High-Risk Subset of Patients. Chest, 2008, 134, 497-506.	0.8	44

#	ARTICLE	IF	CITATIONS
325	Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1641-1647.	0.9	74
326	Spirometer Calibration Checks. <i>Chest</i> , 2007, 131, 1486-1493.	0.8	14
327	Standardization of the Single-Breath Diffusing Capacity in a Multicenter Clinical Trial. <i>Chest</i> , 2007, 132, 1191-1197.	0.8	26
328	Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. <i>New England Journal of Medicine</i> , 2007, 356, 2027-2039.	27.0	184
329	Oxygen Therapy in COPD: What Do We Know?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 321-322.	5.6	5
330	Sex Differences in Severe Pulmonary Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 243-252.	5.6	301
331	Ethical Issues Confronted In Pulmonary Clinical Trials. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 200-205.	3.5	5
332	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	5.6	411
333	Survey on Quality of Training in Pulmonary Physiology During Fellowship. <i>Chest</i> , 2007, 131, 1270-1271.	0.8	0
334	Optimizing Treatment of Chronic Obstructive Pulmonary Disease: An Assessment of Current Therapies. <i>American Journal of Medicine</i> , 2007, 120, S4-S13.	1.5	19
335	Preventing Chronic Obstructive Pulmonary Disease: What Is Known and What Needs to Be Done to Make a Difference to the Patient?. <i>American Journal of Medicine</i> , 2007, 120, S14-S22.	1.5	19
336	Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. <i>Thorax</i> , 2007, 62, 411-415.	5.6	426
337	Field Tests of Exercise in COPD: The Six-Minute Walk Test and the Shuttle Walk Test. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007, 4, 217-223.	1.6	47
338	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007, 56, 1676-1684.	6.7	93
339	Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2007, 56, 4195-4202.	6.7	22
340	The C523A β 2Adrenergic Receptor Polymorphism Associates with Markers of Asthma Severity in African Americans. <i>Journal of Asthma</i> , 2006, 43, 185-191.	1.7	21
341	Effect of Obesity on Clinical Presentation and Response to Treatment in Asthma. <i>Journal of Asthma</i> , 2006, 43, 553-558.	1.7	142
342	Respiratory Physiologic Changes in Pregnancy. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 1-12.	1.9	171

#	ARTICLE	IF	CITATIONS
343	The Value of Forced Expiratory Volume in 1 Second Decline in the Assessment of Chronic Obstructive Pulmonary Disease Progression. <i>American Journal of Medicine</i> , 2006, 119, 4-11.	1.5	142
344	Allergic Rhinitis and Sinusitis in Asthma. <i>Chest</i> , 2006, 130, 429-435.	0.8	123
345	Association of Obesity With Pulmonary and Nonpulmonary Complications of Pregnancy in Asthmatic Women. <i>Obstetrics and Gynecology</i> , 2006, 108, 77-82.	2.4	70
346	Spirometry is related to perinatal outcomes in pregnant women with asthma. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 120-126.	1.3	115
347	Feasibility of Retinoids for the Treatment of Emphysema Study. <i>Chest</i> , 2006, 130, 1334-1345.	0.8	150
348	Variability of Spirometry in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1106-1113.	5.6	56
349	Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1326-1334.	5.6	392
350	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. <i>New England Journal of Medicine</i> , 2006, 354, 2655-2666.	27.0	1,421
351	Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 379-385.	5.6	225
352	Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. <i>Journal of Rheumatology</i> , 2006, 33, 269-74.	2.0	82
353	The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. <i>Annals of Internal Medicine</i> , 2005, 142, 233.	3.9	1,051
354	Physician and patient perceptions in COPD: The COPD Resource Network Needs Assessment Survey. <i>American Journal of Medicine</i> , 2005, 118, 1415.e9-1415.e17.	1.5	144
355	Adult asthma severity in individuals with a history of childhood asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 61-66.	2.9	56
356	Irreversible lung function deficits in young adults with a history of childhood asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 1213-1219.	2.9	51
357	Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 125-129.	1.6	249
358	Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1302-1309.	5.6	102
359	Racial Difference in Lung Function in African-American and White Children: Effect of Anthropometric, Socioeconomic, Nutritional, and Environmental Factors. <i>American Journal of Epidemiology</i> , 2004, 160, 893-900.	3.4	100
360	Asthma During Pregnancy. <i>Obstetrics and Gynecology</i> , 2004, 103, 5-12.	2.4	173

#	ARTICLE	IF	CITATIONS
361	Airway Obstruction Is Common but Unsuspected in Patients Admitted to a General Medicine Service. <i>Chest</i> , 2004, 125, 106-111.	0.8	48
362	Dietary Intake of Soy Genistein is Associated with Lung Function in Patients with Asthma. <i>Journal of Asthma</i> , 2004, 41, 833-843.	1.7	55
363	Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. <i>Clinical Trials</i> , 2004, 1, 326-338.	1.6	13
364	Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 737-744.	1.3	102
365	Efficacy and tolerability of a selective β_2 -adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study. <i>Arthritis and Rheumatism</i> , 2004, 50, 3994-4001.	6.7	74
366	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 717-724.	2.9	93
367	The relationship of asthma medication use to perinatal outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1040-1045.	2.9	189
368	Serum Vitamin Levels and the Risk of Asthma in Children. <i>American Journal of Epidemiology</i> , 2004, 159, 351-357.	3.4	112
369	Acquired Methemoglobinemia. <i>Medicine (United States)</i> , 2004, 83, 265-273.	1.0	284
370	Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. <i>Arthritis and Rheumatism</i> , 2003, 48, 2262-2274.	6.7	107
371	Asthma morbidity during pregnancy can be predicted by severity classification. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 283-288.	2.9	252
372	A Randomized Trial Comparing Lung-Volumeâ€“Reduction Surgery with Medical Therapy for Severe Emphysema. <i>New England Journal of Medicine</i> , 2003, 348, 2059-2073.	27.0	1,842
373	Six-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1522-1527.	5.6	331
374	Changes in Smoking Status Affect Women More than Men: Results of the Lung Health Study. <i>American Journal of Epidemiology</i> , 2003, 157, 973-979.	3.4	107
375	Measurement Variability in Single-Breath Diffusing Capacity of the Lung. <i>Chest</i> , 2003, 123, 1082-1089.	0.8	54
376	Age and Risk of Pulmonary Arterial Hypertension in Scleroderma*. <i>Chest</i> , 2003, 124, 2098-2104.	0.8	113
377	The Effect of Smoking Intervention and an Inhaled Bronchodilator on Airways Reactivity in COPD*. <i>Chest</i> , 2003, 124, 449-458.	0.8	64
378	Lack of Long-term Adverse Adrenal Effects From Inhaled Triamcinolone. <i>Chest</i> , 2003, 124, 57-62.	0.8	27

#	ARTICLE	IF	CITATIONS
379	Confounding Issues in COPD Risk Study?. Chest, 2003, 123, 307-308.	0.8	0
380	Single-Breath Diffusing Capacity of the Lung for Carbon Monoxide. Chest, 2003, 123, 1394-1400.	0.8	36
381	Gene Expression in Bronchoalveolar Lavage Cells from Scleroderma Patients. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 549-557.	2.9	109
382	Body Mass Index and the Risk of COPD. Chest, 2002, 121, 370-376.	0.8	103
383	Paradoxical physical findings described by Kussmaul: pulsus paradoxus and Kussmaul's sign. Lancet, The, 2002, 359, 1940-1942.	13.7	91
384	Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics. Contemporary Clinical Trials, 2002, 23, 87-92.	1.9	5
385	The effect of gender on the relationship between body fat distribution and lung function. Journal of Clinical Epidemiology, 2001, 54, 399-406.	5.0	126
386	Primary Pulmonary Hypertension Is Not Associated With Scleroderma-Like Changes in Nailfold Capillaries. Chest, 2001, 120, 796-800.	0.8	21
387	Post resuscitative and initial utility in life saving efforts (pulse). Resuscitation, 2001, 50, 23-25.	3.0	10
388	Patients at High Risk of Death after Lung-Volumeâ€“Reduction Surgery. New England Journal of Medicine, 2001, 345, 1075-1083.	27.0	612
389	Long-Term Effects of Budesonide or Nedocromil in Children with Asthma. New England Journal of Medicine, 2000, 343, 1054-1063.	27.0	1,376
390	Unpredictability of Deception in Compliance With Physician-Prescribed Bronchodilator Inhaler Use in a Clinical Trial. Chest, 2000, 118, 290-295.	0.8	104
391	Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2000, 343, 1902-1909.	27.0	785
392	Extensive Surface Phenotyping of Alveolar Macrophages in Interstitial Lung Disease. Clinical Immunology, 2000, 94, 33-41.	3.2	42
393	RESPIRATORY PHYSIOLOGIC CHANGES IN PREGNANCY. Immunology and Allergy Clinics of North America, 2000, 20, 663-672.	1.9	13
394	Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis. Annals of Internal Medicine, 2000, 132, 947.	3.9	335
395	A thermal vascular test for distinguishing between patients with Raynaud's Phenomenon and healthy controls.. Health Psychology, 1999, 18, 421-426.	1.6	9
396	Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 1168-1178.	6.7	201

#	ARTICLE	IF	CITATIONS
397	Effects of Multiple Attempts to Quit Smoking and Relapses to Smoking on Pulmonary Function. Journal of Clinical Epidemiology, 1998, 51, 1317-1326.	5.0	89
398	African-American Race and Antibodies to Topoisomerase I Are Associated With Increased Severity of Scleroderma Lung Disease. Chest, 1998, 114, 801-807.	0.8	115
399	Changing Smoking Patterns and Mortality from Chronic Obstructive Pulmonary Disease. Preventive Medicine, 1997, 26, 418-421.	3.4	69
400	Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users. American Journal of Medicine, 1997, 102, 232-238.	1.5	9
401	Skewing of the CDS + T-cell repertoire in the lungs of patients with systemic sclerosis. Human Immunology, 1996, 48, 84-97.	2.4	71
402	Trends in Compliance With Bronchodilator Inhaler Use Between Follow-up Visits in a Clinical Trial. Chest, 1996, 109, 963-968.	0.8	72
403	Selection of Spirometric Measurements in a Clinical Trial, the Lung Health Study. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 675-681.	5.6	33
404	Measuring Adherence to Asthma Medication Regimens. American Journal of Respiratory and Critical Care Medicine, 1994, 149, S69-S76.	5.6	288
405	Metered-Dose Inhaler Adherence in a Clinical Trial. The American Review of Respiratory Disease, 1992, 146, 1559-1564.	2.9	303
406	The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation. The American Review of Respiratory Disease, 1992, 145, 301-310.	2.9	258
407	Nicardipine in the treatment of raynaud's phenomenon. Arthritis and Rheumatism, 1987, 30, 281-286.	6.7	30
408	Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. American Journal of Medicine, 1984, 77, 451-456.	1.5	56
409	Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. American Journal of Medicine, 1984, 77, 1027-1034.	1.5	92
410	Clinical and Demographic Predictors of Loss of Pulmonary Function in Systemic Sclerosis. Medicine (United States), 1984, 63, 221-231.	1.0	67
411	Absence of positional change in pulmonary diffusing capacity in systemic sclerosis. American Journal of Medicine, 1983, 75, 305-312.	1.5	8
412	Reply to: Selecting the Right Patient: The Achilles' Heel of COPD Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	0